Multiple Myeloma Study

Principal Investigator: R. Vinod Parameswaran, MD

Sub-Investigators: Kelly McCaul, MD; Stephen Medlin, DO; Mark Huber, MD; Amy Krie, MD; Michael Robinson, MD; Addison Tolentino, MD; Tammie Smart, CNP; Kristen Hurley, CNP

Study Coordinator: Erika Meyer, RN

Study Description: Bone Marker Directed Dosing of ZOMETA^® (zoledronic acid) for the Prevention of Skeletal Complications in Patients with Advanced Multiple Myeloma

Overview: The purpose of this clinical research study is to determine if a particular dosing method for ZOMETA (zoledronic acid) is safe and effective in preventing skeletal complications in patients with Multiple Myeloma. Participants in this study will receive one of two different dosing schedules. The medication under investigation has already received approval from the U.S. Food and Drug Administration (FDA) but the frequency of dosing with ZOMETA and the method used to determine the dosing frequency being evaluated in this study have not been approved by the FDA for use in the U.S. and are considered experimental.

There is no cost to participants for the procedures, study medications or tests that are required for this research study that are not part of their usual medical care.

Inclusion Criteria:

• Men and women, age 18 and older
• Confirmed diagnosis of Multiple Myeloma
• Stable kidney function

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning to become pregnant
• Bone marrow transplantation within 2 months prior to initial study treatment
• Diagnosis of metabolic bone disease other than osteoporosis

Contact:  Erika Meyer, RN

Phone:    (605) 322-3086

Email:     erika.meyer@avera.org